Evidence map›Paper›PMID 41658944›Full record

ArticleFrontiers in neuroscience2026

Comparative effect of vortioxetine and sertraline on clinical and inflammatory profile in Parkinson's disease with comorbid depression.

Marika Alborghetti, Camilla Moliterni, Edoardo Bianchini, Domiziana Rinaldi, Daniela Caissutti, Antonella Capozzi, Fabiana Giada Radicati, Antonella Moschillo, Martina Marino, Isabella Berardelli and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marika Alborghetti *Department of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Camilla Moliterni *Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Edoardo BianchiniDepartment of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Domiziana RinaldiDepartment of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Daniela CaissuttiDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Antonella CapozziDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Fabiana Giada RadicatiCenter for Parkinson's Disease, IRCCS San Raffaele Pisana, Rome, Italy.
Antonella MoschilloDepartment of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Martina MarinoDepartment of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Isabella BerardelliDepartment of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Marco SalvettiDepartment of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Ferdinando NicolettiIRCCS Neuromed, Pozzilli, Italy.
Roberta MisasiDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Francesco Ernesto PontieriDepartment of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Preclinical and clinical studies suggest that the multimodal antidepressant vortioxetine may offer a valuable therapeutic option in the treatment of depression associated with neurological disorders, including Parkinson's disease (PD). Objectives: To compare the effect of vortioxetine and the SSRI sertraline in the treatment of PD and comorbid depression, placing emphasis on peripheral inflammation markers. Methods: This is an observational longitudinal study. We have recruited 33 patients affected by PD with comorbid depression, evaluated for motor and non-motor symptoms, depression, and peripheral and soluble markers of inflammation at baseline and at the end of antidepressant treatment. Patients were divided into two groups treated with either vortioxetine (10-20 mg/day) or sertraline (50 mg/day) for 4 months. A group of 12 healthy controls was also used for comparative purposes. Results: At baseline PD patients showed a higher number of "classical" monocytes and a lower number of "non-classical" monocytes and myeloid dendritic cells (mDCs). The number and activity of DCs generated from isolated monocytes were also lower in PD patients. While both sertraline and vortioxetine treatment further reduced the number of mDCs, only vortioxetine had a restorative effect on CD40- and CD54-expressing DCs and their function. Both drugs display an antidepressant activity, but vortioxetine was superior to sertraline in improving cognitive function, anxiety, anhedonia, and apathy. Conclusion: These data evaluate for the first time the immunomodulatory effects of two different treatments in PD patients with comorbid depression, highlighting the greater immunomodulatory capacity of vortioxetine.

Indexed as

cognitive impairmentinflammationmajor depressive disorderParkinson’s diseasevortioxetine

Identifiers

PMID41658944
PMCPMC12874709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.